ALT This review examines the therapeutic role of exercise in diabetic cardiomyopathy, a major cardiovascular complication of diabetes. Exercise improves heart health through multiple mechanisms, including reducing inflammation, oxidative stress, fibrosis, and cardiomyocyte apoptosis while enhancing endothelial and mitochondrial function. The authors also discuss emerging evidence that exercise may complement newer antidiabetic medications and improve outcomes in diabetic heart failure. These findings reinforce the importance of lifestyle interventions alongside pharmacological treatments. How can exercise be most effectively integrated into modern diabetes care?

ALT Sonodynamic therapy reduced macrophage-driven inflammation and fibrosis via TLR4/NF-κB signaling in AF models. Is this a future precision approach for arrhythmia management?

ALT In this pilot study, levosimendan improved symptoms, hemodynamics, and echocardiographic parameters within 7 days. Could this reshape acute management of RHF in PH?

ALT This study evaluated whether mean platelet volume (MPV) could predict anticoagulation quality in 370 patients with mechanical heart valves receiving warfarin therapy. Researchers found that MPV did not correlate with time in therapeutic range (TTR) and showed poor ability to identify patients with effective anticoagulation control. However, MPV patterns differed by valve type, with an inverse relationship between MPV and INR observed in mitral valve replacement patients but not in aortic valve replacement patients. Only about one-third of patients achieved effective anticoagulation control, underscoring the ongoing need for improved management strategies and better biomarkers in mechanical heart valve care. The findings raise important questions about valve-specific platelet biology and future approaches to anticoagulation

ALT The COMMIT-LAD Registry is a prospective multicenter study designed to provide real-world insights into the management of significant left anterior descending (LAD) artery disease. By comparing outcomes, symptom burden, and quality of life across treatment approaches, the registry aims to clarify how diffuse and focal CAD differ in practice and prognosis. As patient-centered outcomes become increasingly important, could registries like COMMIT-LAD help refine treatment selection for diffuse CAD? Share your perspective below and repost to continue the conversation

ALT This editorial explores the rationale behind COMMIT-LAD and argues that physiology-based phenotyping may be the key to personalizing treatment for diffuse LAD disease. Rather than viewing optimal medical therapy as a background strategy, the authors highlight the need to define, intensify, and measure it with the same rigor applied to revascularization. The commentary also emphasizes the potential of functional assessment to better match patients to medical therapy, PCI, or CABG. Do you think coronary physiology should play a larger role in treatment selection for diffuse CAD? Share your thoughts and repost to join the discussion.

ALT In hypertensive mice, MRAs did not restore a normal dipping pattern or alter 24h BP rhythms. What does this mean for targeting circadian dynamics in hypertension?

ALT A meta-analysis of RCTs shows ACEi may attenuate LVEF decline—especially in patients receiving trastuzumab. Could this reshape cardio-oncology practice?

ALT A scoping review suggests somatostatin/analogues may safely reduce chest tube output, though one-third still require further intervention. Could earlier or better patient selection improve outcomes?